Salvage radiation therapy (RT) showed efficacy in local control of relapsed or refractory large B-cell lymphoma (LBCL) following CD19-targeted chimeric antigen receptor (CAR) T-cell therapy failure.
A retrospective analysis of the ICOGEN clinical trial demonstrates the utility of VeriStrat to predict outcome in an all Chinese cohort treated with EGFR TKI.